Ergosterol Biosynthesis for the Specific Treatment of Chagas Disease: From Basic Science to Clinical Trials

Trypanosomatid Diseases: Molecular Routes to Drug Discovery

Volumn , Issue , 2013, Pages 489-514

  Urbina, Julio A ^a,b  

^a INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^b NONE   (United States)

Author keywords

14 demethylase; Chagas disease; Clinical trials; Ergosterol biosynthesis inhibitor; Posaconazole; Ravuconazole

Indexed keywords

EID: 84886486052     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527670383.ch26     Document Type: Chapter

References (158)

1. Chagas, C. (1911) Nova entidade morbida do homen. Resumo greal dos estudos etiológicos e clínicos. Mem. Inst. Oswaldo Cruz, 3, 219-275.
2. Aufderheide, A.C., Salo, W., Madden, M., Streitz, J., Buikstra, J., Guhl, F., Arriaza, B. et al. (2004) A 9,000-year record of Chagas' disease. Proc. Natl. Acad Sci. USA, 101, 2034-2039.
3. Hotez, P.J., Bottazzi, M.E., Franco-Paredes, C., Ault, S.K., and Periago, M.R. (2008) The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination. PLoS Negl. Trop. Dis., 2, e300.
4. Schofield, C.J., Jannin, J., and Salvatella, R. (2006) The future of Chagas disease control. Trends Parasitol., 22, 583-588.
5. Tarleton, R.L., Reithinger, R., Urbina, J.A., Kitron, U., and Gurtler, R.E. (2007) The challenges of Chagas disease- grim outlook or glimmer of hope. PLoS Med., 4, e332.
6. Franco-Paredes, C., Bottazzi, M.E., and Hotez, P.J. (2009) The unfinished public health agenda of Chagas disease in the era of globalization. PLoS Negl. Trop. Dis., 3, e470.
7. Gurtler, R.E., Diotaiuti, L., and Kitron, U. (2008) Commentary: Chagas disease: 100 years since discovery and lessons for the future. Int. J. Epidemiol., 37, 698-701.
8. Pinto Dias, J.C. (1999) Epidemiologia, in Trypanosoma cruzi e doenSca de Chagas (eds Z. BrenerZ. Andrade, and C. Barral-Netto), Guanabara Koogan, Rio de Janeiro, pp. 48-74.
9. Bern, C., Montgomery, S.P., Herwaldt, B. L., Rassi, A.Jr., Marin-Neto, J.A., Dantas, R.O., Maguire, J.H. et al. (2007) Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA, 298, 2171-2181.
10. Diaz, J.H. (2007) Chagas disease in the United States: a cause for concern in Louisiana? J. La. State Med. Soc., (21-3), 25-29.
11. Piron, M., Verges, M., Munoz, J., Casamitjana, N., Sanz, S., Maymo, R.M., Hernandez, J.M. et al. (2008) Seroprevalence of Trypanosoma cruzi infection in at-risk blood donors in Catalonia (Spain). Transfusion, 48, 1862- L 1868.
12. Gascon, J., Albajar, P., Canas, E., Flores, M., Gomez Prat, J., Herrera, R.N., Lafuente, C.A. et al. (2007) Diagnosis, management and treatment of chronic Chagas' heart disease in areas where Trypanosoma cruzi infection is not endemic. Rev. Esp. Cardiol., 60, 285-293.
13. Reithinger, R., Tarleton, R.L., Urbina, J.A., Kitron, U., and Gurtler, R.E. (2009) Eliminating Chagas disease: challenges and a roadmap. BMJ, 338, b1283.
14. Dias, J.C., Silveira, A.C., and Schofield, C. J. (2002) The impact of Chagas disease control in Latin America: a review. Mem. Inst. Oswaldo Cruz, 97, 603-612.
15. Rassi, A.Jr., Dias, J.C., Marin-Neto, J.A., and Rassi, A. (2009) Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas disease. Heart., 95, 524-534.
16. Urbina, J.A. and Docampo, R. (2003) Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol., 19, 495-501.
17. Pinto Dias, J.C. (2006) The treatment of Chagas disease (South American trypanosomiasis). Ann. Intern. Med., 144, 772-774.
18. Ribeiro, I., Sevcsik, A.M., Alves, F., Diap, G., Don, R., Harhay, M.O., Chang, S. et al. (2009) New, improved treatments for Chagas disease: from the r&d pipeline to the patients. PLoS Negl. Trop. Dis., 3, e484.
19. Urbina, J.A. (2009) Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop., 115, 55-68.
20. Gutierrez, F.R., Guedes, P.M., Gazzinelli, R.T., and Silva, J.S. (2009) The role of parasite persistence in pathogenesis of Chagas heart disease. Parasite Immunol., 31, 673-685.
21. Brener, Z. and Gazzinelli, R.T. (1997) Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease. Int. Arch. Allergy Immunol., 114, 103-110.
22. + Tcells in Trypanosoma cruzi infection. Curr. Opin. Immunol., 21, 385-390.
23. Marin-Neto, J.A., Cunha-Neto, E., Maciel, B.C., and Simoes, M.V. (2007) Pathogenesis of chronic Chagas heart disease. Circulation, 115, 1109-1123.
24. + Tcells in chronic Chagas' disease patients. Int. Immunol., 18, 465-471.
25. Rassi, A.Jr., Rassi, A., and Little, W.C. (2000) Chagas' heart disease. Clin. Cardiol., 23, 883-889.
26. CanScado, J.R. (2002) Long term evaluation of etiological treatment of Chagas disease with benznidazole. Rev. Inst. Med. Trop. Sao Paulo, 44, 29-37.
27. CanScado, J.R. (1999) Criteria of Chagas disease cure. Mem. Inst. Oswaldo Cruz, (Suppl. 1), 331-336.
28. Rassi, A.Jr., Dias, J.C., Marin-Neto, J.A., and Rassi, A. (2009) Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease. Heart, 95, 524-534.
29. Kirchhoff, L.V. (1999) Chagas' disease (American Trypanosomiasis): a tropical disease now emerging in the United States, in Emerging Infections 3 (eds W.M. ScheldW.A. Craig, and J.M. Hughes), ASM Press, Washington, DC, pp. 111-134.
30. Filardi, L.S. and Brener, Z. (1987) Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans. R. Soc. Trop. Med. Hyg., 81, 755-759.
31. Murta, S.M., Gazzinelli, R.T., Brener, Z., and Romanha, A.J. (1998) Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox. Mol. Biochem. Parasitol., 93, 203-214.
32. Yun, O., Lima, M.A., Ellman, T., Chambi, W., Castillo, S., Flevaud, L., Roddy, P. et al. (2009) Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Medecins sans Frontieres. PLoS. Negl. Trop. Dis., 3, e488.
33. Romanha, A.J., Alves, R.O., Murta, S.M., Silva, J.S., Ropert, C., and Gazzinelli, R.T. (2002) Experimental chemotherapy against Trypanosoma cruzi infection: essential role of endogenous interferongamma in mediating parasitologic cure. J. Infect. Dis., 186, 823-828.
34. Bahia-Oliveira, L.M., Gomes, J.A., Cancado, J.R., Ferrari, T.C., Lemos, E.M., Luz, Z.M., Moreira, M.C. et al. (2000) Immunological and clinical evaluation of chagasic patients subjected to chemotherapy during the acute phase of Trypanosoma cruzi infection 14-30 years ago. J. Infect. Dis., 182, 634-638.
35. Andrade, A.L., Martelli, C.M., Oliveira, R. M., Silva, S.A., Aires, A.I., Soussumi, L. M., Covas, D.T. et al. (2004) Short report: benznidazole efficacy among Trypanosoma cruzi-infected adolescents after a six-year follow-up. Am. J. Trop. Med. Hyg., 71, 594-597.
36. de Andrade, A.L., Zicker, F., de Oliveira, R.M., Almeida Silva, S., Luquetti, A., Travassos, L.R., Almeida, I.C. et al. (1996) Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet, 348, 1407-1413.
37. Sosa-Estani, S. and Segura, E.L. (2006) Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina. Curr. Opin. Infect. Dis., 19, 583-587.
38. Silveira, C.A., Castillo, E., and Castro, C. (2000) Evaluation of an specific treatment for Trypanosoma cruzi in children, in the evolution of the indeterminate phase. Rev. Soc. Bras. Med. Trop., 33, 191-196.
39. Solari, A., Ortiz, S., Soto, A., Arancibia, C., Campillay, R., Contreras, M., Salinas, P. et al. (2001) Treatment of Trypanosoma cruzi-infected children with nifurtimox: a year follow-up by PCR. J. Antimicrob. Chemother., 48, 515-519.
40. Martins, H.R., Figueiredo, L.M., Valamiel-Silva, J.C., Carneiro, C.M., Machado-Coelho, G.L., Vitelli-Avelar, D.M., Bahia, M.T. et al. (2008) Persistence of PCRpositive tissue in benznidazole-treatedmice with negative blood parasitological and serological tests in dual infections with Trypanosoma cruzi stocks from different genotypes. J. Antimicrob. Chemother., 61, 1319-1327.
41. Anez, N., Carrasco, H., Parada, H., Crisante, G., Rojas, A., Fuenmayor, C., Gonzalez, N. et al. (1999) Myocardial parasite persistence in chronic chagasic patients. Am. J. Trop. Med. Hyg., 60, 726-732.
42. Britto, C., Silveira, C., Cardoso, M.A., Marques, P., Luquetti, A., Macedo, V., and Fernandes, O. (2001) Parasite persistence in treated chagasic patients revealed by xenodiagnosis and polymerase chain reaction. Mem. Inst. Oswaldo Cruz, 96, 823-826.
43. Braga, M.S., Lauria-Pires, L., Arganaraz, E.R., Nascimento, R.J., and Teixeira, A.R. (2000) Persistent infections in chronic Chagas' disease patients treated with anti-Trypanosoma cruzi nitroderivatives. Rev. Inst. Med. Trop. Sao Paulo, 42, 157-161.
44. Lauria-Pires, L., Braga, M.S., Vexenat, A. C., Nitz, N., Simoes-Barbosa, A., Tinoco, D.L., and Teixeira, A.R. (2000) Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. Am. J. Trop. Med. Hyg., 63, 111-118.
45. Garcia, S., Ramos, C.O., Senra, J.F., Vilas-Boas, F., Rodrigues, M.M., Campos-de-Carvalho, A.C., Ribeiro-Dos-Santos, R. et al. (2005) Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrob. Agents Chemother., 49, 1521-1528.
46. Fernandes, C.D., Tiecher, F.M., Balbinot, M.M., Liarte, D.B., Scholl, D., Steindel, M., and Romanha, A. (2009) Efficacy of benznidazol treatment for asymptomatic chagasic patients from state of Rio Grande do Sul evaluated during a three years follow-up. Mem. Inst. Oswaldo Cruz, 104, 27-32.
47. Krautz, G.M., Kissinger, J.C., and Krettli, A.U. (2000) The targets of the lytic antibody response against Trypanosoma cruzi. Parasitol. Today, 16, 31-34.
48. Krautz, G.M., Galvao, L.M., Cancado, J.R., Guevara-Espinoza, A., Ouaissi, A., and Krettli, A.U. (1995) Use of a 24-kilodalton Trypanosoma cruzi recombinant protein to monitor cure of human Chagas' disease. J. Clin. Microbiol., 33, 2086-2090.
49. Pereira-Chioccola, V.L., Fragata-Filho, A. A., Levy, A.M., Rodrigues, M.M., and Schenkman, S. (2003) Enzyme-linked immunoassay using recombinant transsialidase of Trypanosoma cruzi can be employed for monitoring of patients with Chagas' disease after drug treatment. Clin. Diagn. Lab. Immunol., 10, 826-830.
50. Buckner, F.S. (2008) Sterol 14-demethylase inhibitors for Trypanosoma cruzi infections. Adv. Exp. Med. Biol., 625, 61-80.
51. Viotti, R. and Vigliano, C. (2007) Etiological treatment of chronic Chagas disease: neglected 'evidence' by evidencebased medicine. Expert Rev. Anti Infect. Ther., 5, 717-726.
52. Viotti, R., Vigliano, C., Lococo, B., Bertocchi, G., Petti, M., Alvarez, M.G., Postan, M. et al. (2006) Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann. Intern. Med., 144, 724-734.
53. Viotti, R., Vigliano, C., Alvarez, M.G., Lococo, B., Petti, M., Bertocchi, G., Armenti, A. et al. (2011) Impact of aetiological treatment on conventional and multiplex serology in chronic Chagas disease. PLoS Negl. Trop. Dis., 5, e1314.
54. Docampo, R. (1990) Sensitivity of parasites to free radical damage by antiparasitic drugs. Chem. Biol. Interact., 73, 1-27.
55. Pinazo, M.J., Munoz, J., Posada, E., Lopez-Chejade, P., Gallego, M., Ayala, E., Del Cacho, E. et al. (2010) Tolerance of benznidazole in the treatment of Chagas disease in adults. Antimicrob. Agents Chemother., 54, 4896-4899.
56. Urbina, J.A. (2010) New insights in Chagas' disease treatment. Drugs Future, 35, 409-419.
57. Urbina, J.A. (2010) Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop., 115, 55-68.
58. Rassi, A.Jr., Rassi, A., and Marin-Neto, J. A. (2009) Chagas heart disease: pathophysiologic mechanisms, prognostic factors and risk stratification. Mem. Inst. Oswaldo Cruz, 104 (Suppl. 1), 152-158.
59. Kalil, J. and Cunha-Neto, E. (1996) Autoimmunity in Chagas disease cardiomyopathy: fullfilling the criteria at last? Parasitol. Today, 12, 396-399.
60. Cunha-Neto, E., Duranti, M., Gruber, A., Zingales, B., De Messias, I., Stolf, N., Bellotti, G. et al. (1995) Autoinmunity in Chagas disease cardiopathy: biological relevance of a cardiac myosin-specific epitope crossreactive to an inmunodominant Trypanosoma cruzi antigen. Proc. Natl. Acad. Sci. USA, 92, 3541-3545.
61. Urbina, J.A. (1999) Parasitological cure of Chagas disease: is it possible?, Is it relevant? Mem. Inst. Oswaldo Cruz, (Suppl. 1), 349-355.
62. Croft, S.L., Barrett, M.P., and Urbina, J.A. (2005) Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol., 21, 508-512.
63. Tarleton, R.L. (2001) Parasite persistence in the aetiology of Chagas disease. Int. J. Parasitol., 31, 550-554.
64. Apt, W., Heitmann, I., Jercic, L., Jofré, L., Muñoz, P., Noemí, I., San Martin, A.M. et al. (2008) Tratamiento antiparasitario de la enfremedad de Chagas. Rev. Chil. Infect., 25, 384-389.
65. Marin-Neto, J.A., Rassi, A.Jr., Morillo, C. A., Avezum, A., Connolly, S.J., Sosa-Estani, S., Rosas, F. et al. (2008) Rationale and design of a randomized placebocontrolled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am. Heart J., 156, 37-43.
66. Daum, G., Lees, N.D., Bard, M., and Dickson, R. (1998) Biochemistry, cell biology and molecular biology of lipids of Saccharomyces cerevisiae. Yeast, 14, 1471-1510.
67. Furlong, S.T. (1989) Sterols of parasitic protozoa and helminths. Exp. Parasitol., 68, 482-485.
68. Korn, E.D., Von Brand, T., and Tobie, E.J. (1969) The sterols of Trypanosoma cruzi and Crithidia fasciculata. Comp. Biochem. Physiol., 30, 601-610.
69. Liendo, A., Lazardi, K., and Urbina, J.A. (1998) In-vitro antiproliferative effects and mechanism of action of the bis-triazole D0870 and its S(-) enantiomer against Trypanosoma cruzi. J. Antimicrob. Chemother., 41, 197-205.
70. Liendo, A., Visbal, G., Piras, M.M., Piras, R., and Urbina, J.A. (1999) Sterol composition and biosynthesis in Trypanosoma cruzi amastigotes. Mol. Biochem. Parasitol., 104, 81-91.
71. Urbina, J.A. (2009) Ergosterol biosynthesis and drug development for Chagas disease. Mem. Inst. Oswaldo Cruz, (Suppl. 1), 311-318.
72. Urbina, J.A., Vivas, J., Ramos, H., Larralde, G., Aguilar, Z., and Avilan, L. (1988) Alteration of lipid order profile and permeability of plasma membranes from Trypanosoma cruzi epimastigotes grown in the presence of ketoconazole. Mol. Biochem. Parasitol., 30, 185-195.
73. Contreras, L.M., Vivas, J., and Urbina, J.A. (1997) Altered lipid composition and enzyme activities of plasma membranes from Trypanosoma (Schizotrypanum) cruzi epimastigotes grown in the presence of sterol biosynthesis inhibitors. Biochem. Pharmacol., 53, 697-704.
74. Montez, B., Oldfield, E., Urbina, J.A., Pekerar, S., Husted, C., and Patterson, J. (1993) Editing 13C-NMR spectra of membranes. Biochim. Biophys. Acta, 1152, 314-318.
75. Urbina, J.A., Pekerar, S., Le, H.B., Patterson, J., Montez, B., and Oldfield, E. (1995) Molecular order and dynamics of phosphatidylcholine bilayer membranes in the presence of cholesterol, ergosterol and lanosterol: a comparative study using 2H-, 13C- and 31P-NMR spectroscopy. Biochim. Biophys. Acta, 1238, 163-176.
76. Urbina, J.A., Moreno, B., Arnold, W., Taron, C.H., Orlean, P., and Oldfield, E. (1998) A carbon-13 nuclear magnetic resonance spectroscopic study of interproton pair order parameters: a new approach to study order and dynamics in phospholipid membrane systems. Biophys. J., 75, 1372-1383.
77. Lazardi, K., Urbina, J.A., and de Souza,W. (1990) Ultrastructural alterations induced by two ergosterol biosynthesis inhibitors, ketoconazole and terbinafine, on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother., 34, 2097-2105.
78. Lazardi, K., Urbina, J.A., and de Souza,W. (1991) Ultrastructural alterations induced by ICI 195,739, a bis-triazole derivative with strong antiproliferative action against Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother., 35, 736-740.
79. Rodrigues, C.O., Catisti, R., Uyemura, S. A., Vercesi, A.E., Lira, R., Rodriguez, C., Urbina, J.A. et al. (2001) The sterol composition of Trypanosoma cruzi changes after growth in different culture media and results in different sensitivity to digitonin-permeabilization. J. Eukaryot. Microbiol., 48, 588-594.
80. Urbina, J.A., Payares, G., Molina, J., Sanoja, C., Liendo, A., Lazardi, K., Piras, M.M. et al. (1996) Cure of short- and longterm experimental Chagas' disease using D0870. Science, 273, 969-971.
81. Urbina, J.A., Payares, G., Contreras, L.M., Liendo, A., Sanoja, C., Molina, J., Piras, M. et al. (1998) Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob. Agents Chemother., 42, 1771-1777.
82. Lepesheva, G.I., Zaitseva, N.G., Nes, W. D., Zhou,W., Arase, M., Liu, J., Hill, G.C. et al. (2006) CYP51 from Trypanosoma cruzi: a phyla-specific residue in the B0 helix defines substrate preferences of sterol 14alpha-demethylase. J. Biol. Chem., 281, 3577-3585.
83. Fischer, R.T., Stam, S.H., Johnson, P.R., Ko, S.S., Magolda, R.L., Gaylor, J.L., and Trzaskos, J.M. (1989) Mechanistic studies of lanosterol 14 alpha-methyl demethylase: substrate requirements for the component reactions catalyzed by a single cytochrome P-450 isozyme. J. Lipid. Res., 30, 1621-1632.
84. Lepesheva, G.I., Villalta, F., and Waterman, M.R. (2011) Targeting Trypanosoma cruzi sterol 14alphademethylase (CYP51). Adv. Parasitol., 75, 65-87.
85. Walker, K.A., Kertesz, D.J., Rotstein, D. M., Swinney, D.C., Berry, P.W., So, O.Y., Webb, A.S. et al. (1993) Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering. J. Med. Chem., 36, 2235-2237.
86. Lepesheva, G.I., Hargrove, T.Y., Anderson, S., Kleshchenko, Y., Furtak, V., Wawrzak, Z., Villalta, F. et al. (2010) Structural insights into inhibition of sterol 14alpha-demethylase in the human pathogen Trypanosoma cruzi. J. Biol. Chem., 285, 25582-25590.
87. Chen, C.K., Leung, S.S., Guilbert, C., Jacobson, M.P., McKerrow, J.H., and Podust, L.M. (2010) Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole. PLoS Negl. Trop. Dis., 4, e651.
88. Hargrove, T.Y.,Wawrzak, Z., Liu, J., Waterman, M.R., Nes, W.D., and Lepesheva, G.I. (2012) Structural complex of sterol 14alpha-demethylase (CYP51) with 14alpha-methylenecyclopropyl-{delta}7-24,25-dihydrolanosterol. J. Lipid. Res., 52, 311-320.
89. Urbina, J.A. (2002) Chemotherapy of Chagas disease. Curr. Pharm. Design, 8, 287-295.
90. Urbina, J.A. (1999) Chemotherapy of Chagas' disease: the how and the why. J. Mol. Med., 77, 332-338.
91. Campoli, P., Al Abdallah, Q., Robitaille, R., Solis, N.V., Fielhaber, J.A., Kristof, A. S., Laverdiere, M. et al. (2011) Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis. Antimicrob. Agents Chemother., 55, 5732-5739.
92. Silva, D.T., de Meirelles Mde, N., Almeida, D., Urbina, J.A., and Pereira, M. C. (2006) Cytoskeleton reassembly in cardiomyocytes infected by Trypanosoma cruzi is triggered by treatment with ergosterol biosynthesis inhibitors. Int. J. Antimicrob. Agents, 27, 530-537.
93. Ferraz, M.L., Gazzinelli, R.T., Alves, R.O., Urbina, J.A., and Romanha, A.J. (2007) The anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole. Antimicrob. Agents Chemother., 51, 1359-1364.
94. + T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection. Antimicrob. Agents Chemother., 53, 174-179.
95. Olivieri, B.P., Molina, J.T., de Castro, S.L., Pereira, M.C., Calvet, C.M., Urbina, J.A., and Araujo-Jorge, T.C. (2010) A comparative study of posaconazole and benznidazole in the prevention of heart damage and promotion of trypanocidal immune response in a murine model of Chagas disease. Int. J. Antimicrob. Agents, 36, 79-83.
96. Pinazo, M.J., Espinosa, G., Gallego, M., Lopez-Chejade, P.L., Urbina, J.A., and Gascon, J. (2010) Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. Am. J. Trop. Med. Hyg., 82, 583-587.
97. Lyseng-Williamson, K.A. (2011) Posaconazole: a pharmacoeconomic review of its use in the prophylaxis of invasive fungal disease in immunocompromised hosts. Pharmacoeconomics, 29, 251-268.
98. Morris, M.I. (2009) Posaconazole: a new oral antifungal agent with an expanded spectrum of activity. Am. J. Health Syst. Pharm., 66, 225-236.
99. Danzon, P.M. (2007) At what price? Nature, 449, 176-179.
100. Corrales, M., Cardozo, R., Segura, M.A., Urbina, J.A., and Basombrio, M.A. (2005) Comparative efficacies of TAK-187, a longlasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease. Antimicrob. Agents Chemother., 49, 1556-1560.
101. Urbina, J.A., Payares, G., Sanoja, C., Molina, J., Lira, R., Brener, Z., and Romanha, A.J. (2003) Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Int. J. Antimicrob. Agents, 21, 39-48.
102. Urbina, J.A., Lira, R., Visbal, G., and Bartrolí, J. (2000) In Vitro Antiproliferative Effects and Mechanism of Action of the New Triazole Derivative UR-9825 Against the Protozoan Parasite Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother., 44, 2498-2502.
103. Guedes, P.M., Urbina, J.A., de Lana, M., Afonso, L.C., Veloso, V.M., Tafuri, W.L., Machado-Coelho, G.L. et al. (2004) Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts. Antimicrob. Agents Chemother., 48, 4286-4292.
104. Urbina, J.A., Payares, G., Sanoja, C., Lira, R., and Romanha, A.J. (2003) In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Intern. J. Antimicrob. Agents, 21, 27-38.
105. Diniz Lde, F., Caldas, I.S., Guedes, P.M., Crepalde, G., de Lana, M., Carneiro, C.M., Talvani, A. et al. (2010) Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. Antimicrob. Agents Chemother., 54, 2979-2986.
106. Andes, D., Marchillo, K., Stamstad, T., and Conklin, R. (2003) In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob. Agents Chemother., 47, 1193-1199.
107. Mikamo, H., Yin, X.H., Hayasaki, Y., Shimamura, Y., Uesugi, K., Fukayama, N., Satoh, M. et al. (2002) Penetration of ravuconazole, a new triazole antifungal, into rat tissues. Chemotherapy, 48, 7-9.
108. Pasqualotto, A.C. and Denning, D.W. (2008) New and emerging treatments for fungal infections. J. Antimicrob. Chemother., 61 (Suppl. 1), 19-30.
109. Kraus, J.M., Verlinde, C.L., Karimi, M., Lepesheva, G.I., Gelb, M.H., and Buckner, F.S. (2009) Rational modification of a candidate cancer drug for use against Chagas disease. J. Med. Chem., 52, 1639-1647.
110. Hucke, O., Gelb, M.H., Verlinde, C.L., and Buckner, F.S. (2005) The protein farnesyltransferase inhibitor tipifarnib as a new lead for the development of drugs against Chagas disease. J. Med. Chem., 48, 5415-5418.
111. Buckner, F., Yokoyama, K., Lockman, J., Aikenhead, K., Ohkanda, J., Sadilek, M., Sebti, S. et al. (2003) A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. Proc. Natl. Acad. Sci. USA, 100, 15149-15153.
112. Kraus, J.M., Tatipaka, H.B., McGuffin, S. A., Chennamaneni, N.K., Karimi, M., Arif, J., Verlinde, C.L. et al. (2010) Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery. J. Med. Chem., 53, 3887-3898.
113. Lepesheva, G.I., Hargrove, T.Y., Kleshchenko, Y., Nes, W.D., Villalta, F., and Waterman, M.R. (2008) CYP51: a major drug target in the cytochrome P450 superfamily. Lipids, 43, 1117-1125.
114. Lepesheva, G.I., Ott, R.D., Hargrove, T.Y., Kleshchenko, Y.Y., Schuster, I., Nes, W.D., Hill, G.C. et al. (2007) Sterol 14alphademethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth. Chem. Biol., 14, 1283-1293.
115. Lepesheva, G.I., Park, H.W., Hargrove, T. Y., Vanhollebeke, B., Wawrzak, Z., Harp, J.M., Sundaramoorthy, M. et al. (2010) Crystal structures of Trypanosoma brucei sterol 14alpha-demethylase and implications for selective treatment of human infections. J. Biol. Chem., 285, 1773-1780.
116. Konkle, M.E., Hargrove, T.Y., Kleshchenko, Y.Y., von Kries, J.P., Ridenour,W., Uddin, M.J., Caprioli, R.M. et al. (2009) Indomethacin amides as a novel molecular scaffold for targeting Trypanosoma cruzi sterol 14alphademethylase. J. Med. Chem., 52, 2846-2853.
117. Chen, C.K., Doyle, P.S., Yermalitskaya, L. V., Mackey, Z.B., Ang, K.K., McKerrow, J. H., and Podust, L.M. (2009) Trypanosoma cruzi CYP51 inhibitor derived from a Mycobacterium tuberculosis screen hit. PLoS Negl. Trop. Dis., 3, e372.
118. Doyle, P.S., Chen, C.K., Johnston, J.B., Hopkins, S.D., Leung, S.S., Jacobson, M. P., Engel, J.C. et al. (2010) A non-azole CYP51 inhibitor cures chagas disease in a mouse model of acute infection. Antimicrob. Agents Chemother., 54, 2480-2488.
119. Buckner, F.S., Griffin, J.H., Wilson, A.J., and Van Voorhis, W.C. (2001) Potent anti-Trypanosma cruzi activities of oxidosqualene cyclase inhibitors. Antimicrob. Agents Chemother., 45, 1210-1215.
120. Buckner, F.S., Nguyen, L.N., Joubert, B. M., and Matsuda, S.P. (2000) Cloning and expression of the Trypanosoma brucei lanosterol synthase gene. Mol. Biochem. Parasitol., 110, 399-403.
121. Joubert, B.M., Buckner, F.S., and Matsuda, S.P. (2001) Trypanosome and animal lanosterol synthases use different catalytic motifs. Org. Lett., 14, 1957-1960.
122. Hinshaw, J.C., Suh, D.Y., Garnier, P., Buckner, F.S., Eastman, R.T., Matsuda, S. P., Joubert, B.M. et al. (2003) Oxidosqualene cyclase inhibitors as antimicrobial agents. J. Med. Chem., 46, 4240-4243.
123. Urbina, J.A. (2003) New chemotherapeutic approaches for the treatment of Chagas disease (American Trypanosomiasis). Expert Opin. Ther. Pat, 13, 661-669.
124. Rosenbaum, M.B., Chiale, P.A., Haedo, A., Lazzari, J.O., and Elizari, M.V. (1983) Ten years of experience with amiodarone. Am. Heart J., 106, 957-964.
125. Benaim, G., Sanders, J.M., Garcia-Marchan, Y., Colina, C., Lira, R., Caldera, A.R., Payares, G. et al. (2006) Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J. Med. Chem., 49, 892-899.
126. Adesse, D., Azzam, E.M., Meirelles Mde, N., Urbina, J.A., and Garzoni, L.R. (2011) Amiodarone inhibits Trypanosoma cruzi infection and promotes cardiac cell recovery with gap junction and cytoskeleton reassembly in vitro. Antimicrob. Agents Chemother., 55, 203-210.
127. Paniz-Mondolfi, A.E., Perez-Alvarez, A. M., Lanza, G., Marquez, E., and Concepcion, J.L. (2009) Amiodarone and itraconazole: a rational therapeutic approach for the treatment of chronic Chagas' disease. Chemotherapy, 55, 228-233.
128. + homeostasis and biosynthesis of sterols in Leishmania mexicana. Antimicrob. Agents Chemother., 53, 1403-1410.
129. Serrano-Martin, X., Payares, G., De Lucca, M., Martinez, J.C., Mendoza-Leon, A., and Benaim, G. (2009) Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis. Antimicrob. Agents Chemother., 53, 5108-5113.
130. Paniz-Mondolfi, A.E., Perez-Alvarez, A. M., Reyes-Jaimes, O., Socorro, G., Zerpa, O., Slova, D., and Concepcion, J.L. (2008) Concurrent Chagas' disease and borderline disseminated cutaneous leishmaniasis: the role of amiodarone as an antitrypanosomatidae drug. Ther. Clin. Risk Manag., 4, 659-663.
131. Tansey, T.R. and Shechter, I. (2001) Squalene synthase: structure and regulation. Prog. Nucleic Acid Res. Mol. Biol., 65, 157-195.
132. Menys, V.C. and Durrington, P.N. (2003) Squalene synthase inhibitors. Br. J. Pharmacol., 139, 881-882.
133. Charlton-Menys, V. and Durrington, P.N. (2007) Squalene synthase inhibitors: clinical pharmacology and cholesterollowering potential. Drugs, 67, 11-16.
134. Suckling, K.E. (2006) The return of two old targets? Expert Opin. Ther. Targets, 10, 785-788.
135. Urbina, J.A., Concepcion, J.L., Rangel, S., Visbal, G., and Lira, R. (2002) Squalene synthase as a chemotherapeutic target in Trypanosoma cruzi and Leishmania mexicana. Mol. Biochem. Parasitol., 125, 35-45.
136. Urbina, J.A., Concepcion, J.L., Caldera, A., Payares, G., Sanoja, C., Otomo, T., and Hiyoshi, H. (2004) In vitro and in vivo activities of E5700 and ER-119884, two novel orally active squalene synthase inhibitors, against Trypanosoma cruzi. Antimicrob. Agents Chemother., 48, 2379-2387.
137. McTaggart, F., Brown, G.R., Davidson, R. G., Freeman, S., Holdgate, G.A., Mallion, K.B., Mirrlees, D.J. et al. (1996) Inhibition of squalene synthase of rat liver by novel substituted quinuclidines. Biochem. Pharmacol., 51, 1477-1487.
138. Ward, W.H.J., Holdgate, G.A., Freeman, S., McTaggart, F., Girdwood, P.A., Davidson, R.G., Mallion, K.B. et al. (1996) Inhibition of squalene synthase in vitro by 3-(biphenyl-4-yl)-quinuclidine. Biochem. Pharmacol., 51, 1489-1501.
139. Ishihara, T., Kakuta, H., Moritani, H., Ugawa, T., Sakamoto, S., Tsukamoto, S., and Yanagisawa, I. (2003) Syntheses and biological evaluation of novel quinuclidine derivatives as squalene synthase inhibitors. Bioorg. Med. Chem., 11, 2403-2414.
140. Ishihara, T., Kakuta, H., Moritani, H., Ugawa, T., and Yanagisawa, I. (2004) Synthesis and biological evaluation of quinuclidine derivatives incorporating phenothiazine moieties as squalene synthase inhibitors. Chem. Pharm. Bull. (Tokyo), 52, 1204-1209.
141. Goldstein, J.L. and Brown, M.S. (2001) The cholesterol quartet. Science, 292, 1310-1312.
142. Orenes Lorente, S., Gomez, R., Jimenez, C., Cammerer, S., Yardley, V., de Luca-Fradley, K., Croft, S.L. et al. (2005) Biphenylquinuclidines as inhibitors of squalene synthase and growth of parasitic protozoa. Bioorg. Med. Chem., 13, 3519-3529.
143. Sealey-Cardona, M., Cammerer, S., Jones, S., Ruiz-Perez, L.M., Brun, R., Gilbert, I. H., Urbina, J.A. et al. (2007) Kinetic characterization of squalene synthase from Trypanosoma cruzi: Selective inhibition by quinuclidine derivatives. Antimicrob. Agents Chemother., 51, 2123-2129.
144. Elhalem, E., Bailey, B.N., Docampo, R., Ujvary, I., Szajnman, S.H., and Rodriguez, J.B. (2002) Design, synthesis, and biological evaluation of aryloxyethyl thiocyanate derivatives against Trypanosoma cruzi. J. Med. Chem., 45, 3984-3999.
145. Szajnman, S.H., Yan, W., Bailey, B.N., Docampo, R., Elhalem, E., and Rodriguez, J.B. (2000) Design and synthesis of aryloxyethyl thiocyanate derivatives as potent inhibitors of Trypanosoma cruzi proliferation. J. Med. Chem., 43, 1826-1840.
146. Urbina, J.A., Concepcion, J.L., Montalvetti, A., Rodriguez, J.B., and Docampo, R. (2003) Mechanism of action of 4-phenoxyphenoxyethyl thiocyanate (WC-9) against Trypanosoma cruzi, the causative agent of Chagas' disease. Antimicrob. Agents Chemother., 47, 2047-2050.
147. Gerpe, A., Odreman-Nunez, I., Draper, P., Boiani, L., Urbina, J.A., Gonzalez, M., and Cerecetto, H. (2008) Heteroallylcontaining 5-nitrofuranes as new anti-Trypanosoma cruzi agents with a dual mechanism of action. Bioorg. Med. Chem., 16, 569-577.
148. Araujo, M.S.,Martins-Filho, O.A., Pereira, M.E., and Brener, Z. (2000) A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas' disease. J. Antimicrob. Chemother., 45, 819-824.
149. Urbina, J.A., Lazardi, K., Aguirre, T., Piras, M.M., and Piras, R. (1988) Antiproliferative synergism of the allylamine SF 86-327 and ketoconazole on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother., 32, 1237-1242.
150. Urbina, J.A., Lazardi, K., Marchan, E., Visbal, G., Aguirre, T., Piras, M.M., Piras, R. et al. (1993) Mevinolin (lovastatin) potentiates the antiproliferative effects of ketoconazole and terbinafine against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob. Agents Chemother., 37, 580-591.
151. Urbina, J.A., Vivas, J., Lazardi, K., Molina, J., Payares, G., Piras, M.M., and Piras, R. (1996) Antiproliferative effects of delta 24(25) sterol methyl transferase inhibitors on Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Chemotherapy, 42, 294-307.
152. Santa-Rita, R.M., Lira, R., Barbosa, H.S., Urbina, J.A., and de Castro, S.L. (2005) Anti-proliferative synergy of lysophospholipid analogues and ketoconazole against Trypanosoma cruzi (Kinetoplastida: Trypanosomatidae): cellular and ultrastructural analysis. J. Antimicrob. Chemother., 55, 780-784.
153. Davidson, M.H. (2007) Squalene synthase inhibition: a novel target for the management of dyslipidemia. Curr. Atheroscler. Rep., 9, 78-80.
154. Burnett, J.R. (2006) Drug evaluation: TAK-475-an oral inhibitor of squalene synthase for hyperlipidemia. Curr. Opin. Investig. Drugs, 7, 850-856.
155. Bahia, M.T. (2011) Evaluation of combined therapies for the treatment of Chagas disease (in portuguese), presented at 27th Reuniao Anual de Pesquisa Aplicada de DoenSca de Chagas, Uberaba, Minas Gerais.
156. Laucella, S.A., Mazliah, D.P., Bertocchi, G., Alvarez, M.G., Cooley, G., Viotti, R., Albareda, M.C. et al. (2009) Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. Clin. Infect. Dis., 49, 1675-1684.
157. Cooley, G., Etheridge, R.D., Boehlke, C., Bundy, B.,Weatherly, D.B., Minning, T., Haney, M. et al. (2008) High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection. PLoS Negl. Trop. Dis., 2, e316.
158. Urbina, J.A. (2009) New advances in the management of a long-neglected disease. Clin. Infect. Dis., 49, 1685-1687.